摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

环香豆素 | 518-20-7

中文名称
环香豆素
中文别名
吡喃香豆素
英文名称
cyclocoumarol
英文别名
pyranocoumarin;2-methoxy-2-methyl-4-phenyl-3,4-dihydro-2H-pyrano[3,2-c]chromen-5-one;2-Methoxy-2-methyl-4-phenyl-3,4-dihydro-2H-pyrano[3,2-c]chromen-5-on;Cyclocumarol;2-methoxy-2-methyl-4-phenyl-3,4-dihydropyrano[3,2-c]chromen-5-one
环香豆素化学式
CAS
518-20-7
化学式
C20H18O4
mdl
——
分子量
322.361
InChiKey
ZGFASEKBKWVCGP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    166°
  • 沸点:
    488.6±45.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    3.7
  • 重原子数:
    24
  • 可旋转键数:
    2
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.25
  • 拓扑面积:
    44.8
  • 氢给体数:
    0
  • 氢受体数:
    4

安全信息

  • 危险等级:
    6.1(b)
  • 危险品标志:
    T+
  • 安全说明:
    S28,S36/37,S45
  • 危险类别码:
    R27
  • WGK Germany:
    3
  • 海关编码:
    2932999099
  • 包装等级:
    III
  • 危险类别:
    6.1(b)
  • 危险品运输编号:
    UN 2811

SDS

SDS:7ffc069a88c6579b2eb630469252d9f6
查看

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    环香豆素盐酸 作用下, 以 丙酮 为溶剂, 反应 4.0h, 生成 warfarin
    参考文献:
    名称:
    华法林及其酚类代谢产物的高产率合成:新化合物。
    摘要:
    DOI:
    10.1002/jps.2600720732
  • 作为产物:
    描述:
    苄叉丙酮吡啶盐酸 作用下, 生成 环香豆素
    参考文献:
    名称:
    Studies on 4-Hydroxycoumarins. V. The Condensation of α,β-Unsaturated Ketones with 4-Hydroxycoumarin1
    摘要:
    DOI:
    10.1021/ja01234a019
点击查看最新优质反应信息

文献信息

  • CHELATE NANOEMULSION FOR MRI
    申请人:Port Marc
    公开号:US20130309176A1
    公开(公告)日:2013-11-21
    The present invention relates to an oil-in-water nanoemulsion composition for MRI, comprising: an aqueous phase, representing 70% to 90% by weight of the composition, advantageously 75% to 85% and more advantageously from 78% to 82% a lipid phase comprising an oil, representing 9.5% to 29.5% by weight of the composition, advantageously 14% to 25% and more advantageously 17% to 21%, a surfactant at the interface between the aqueous and lipid phases, the surfactant comprising at least one amphiphilic paramagnetic metal chelate and optionally an amphiphilic lipid; the total content of surfactant by weight relative to the oil being between 4% and 10% and advantageously between 5% and 8%; the total content of surfactant by weight relative to the composition being between 0.35% and 2.95% and advantageously between 0.5% and 2%; the oil comprising at least 70%, advantageously at least 80%, advantageously at least 95% by weight and especially at least 97% of saturated C6-C18, advantageously C6-C14 and more advantageously C6-C10 fatty acids.
    本发明涉及一种用于磁共振成像的油包水纳米乳液组合物,包括: 水相,表示组合物重量的70%至90%,优选75%至85%,更优选78%至82%; 脂相包括一种油,表示组合物重量的9.5%至29.5%,优选14%至25%,更优选17%至21%; 表面活性剂位于水相和脂相之间的界面上,表面活性剂包括至少一种两性磁性金属螯合物和可选的两性脂质; 相对于油的重量,表面活性剂的总含量在4%至10%之间,优选在5%至8%之间; 相对于组合物的重量,表面活性剂的总含量在0.35%至2.95%之间,优选在0.5%至2%之间; 油包括至少70%,优选至少80%,优选至少95%的饱和C6-C18,优选C6-C14,更优选C6-C10脂肪酸。
  • 4-SUBSTITUTED COUMARIN DERIVATIVES AND PREPARATION METHODS AND USES THEREOF
    申请人:CHEN Lijuan
    公开号:US20180282315A1
    公开(公告)日:2018-10-04
    The present invention pertains to the field of chemical medicine, particularly to 4-substituted coumarin derivatives and preparation methods and applications thereof. The invention provides 4-substituted coumarin derivatives with a structural formula as shown in Formula I. The invention also provides preparation methods and applications for the above 4-substituted coumarin derivatives. The compounds provided in the invention have strong anti-tumor activity with IC50 for plural tumor cell lines between 0.01-5 nM, and it also performs better to inhibit microtubule polymerization and has diversified biological activities and low toxicity, providing new options for drug-sensitive and drug-resistant tumor cells.
    本发明涉及化学药品领域,特别是4-取代香豆素衍生物及其制备方法和应用。该发明提供了具有如公式I所示结构式的4-取代香豆素衍生物。该发明还提供了上述4-取代香豆素衍生物的制备方法和应用。本发明提供的化合物在多种肿瘤细胞系中具有强大的抗肿瘤活性,IC50在0.01-5 nM之间,并且在抑制微管聚合方面表现更好,具有多样化的生物活性和低毒性,为药物敏感和耐药肿瘤细胞提供了新选择。
  • [EN] DIGLYCIDIC ETHER DERIVATIVE THERAPEUTICS AND METHODS FOR THEIR USE<br/>[FR] PRODUITS THÉRAPEUTIQUES DÉRIVÉS D'ÉTHERS DIGLYCIDIQUES ET LEURS PROCÉDÉS D'UTILISATION
    申请人:BRITISH COLUMBIA CANCER AGENCY
    公开号:WO2010000066A1
    公开(公告)日:2010-01-07
    This invention provides compound having a structure of Formula I or Formula II. Uses of such compounds for treatment of various indications, including prostate cancer as well as methods of treatment involving such compounds are also provided.
    这项发明提供了具有化学结构为式I或式II的化合物。还提供了这些化合物用于治疗各种适应症,包括前列腺癌的用途,以及涉及这些化合物的治疗方法。
  • Vectorised Magnetic Emulsion
    申请人:GUERBET
    公开号:US20150320889A1
    公开(公告)日:2015-11-12
    An oil-in-water nanoemulsion composition for MRI, comprising an aqueous phase, a lipid phase as nanodroplets comprising an oil and magnetic particles based on an iron compound and covered with one or several C8-C22 fatty acids, and a mixture of surfactants at the interface between the aqueous and lipid phases, the mixture of surfactants comprising at least one amphiphilic lipid and at least one amphiphilic targeting ligand.
    一种用于磁共振成像的油包水纳米乳液组合物,包括水相、作为纳滴的脂肪相,其中包括一种油和基于铁化合物的磁性粒子,并且被一种或几种C8-C22脂肪酸覆盖,以及存在于水相和脂肪相之间界面的表面活性剂混合物,该表面活性剂混合物包括至少一种两性脂质和至少一种两性靶向配体。
  • [EN] INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS<br/>[FR] INHIBITEURS DE LA GLUCOSE-6-PHOSPHATE DÉSHYDROGÉNASE PERMETTANT DE TRAITER DES AFFECTIONS CARDIOVASCULAIRES ET PULMONAIRES
    申请人:GUPTE SACHIN A
    公开号:WO2018093856A1
    公开(公告)日:2018-05-24
    The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof.
    本公开提供了用于治疗或预防受试者的心血管疾病和/或相关肺部疾病的方法。在某些实施例中,该方法包括向受试者投予治疗有效量的葡萄糖-6-磷酸脱氢酶(G6PD)抑制剂,或其药用可接受的盐、非盐非晶形态、溶剂合物、多形态、互变异构体或前药。
查看更多

表征谱图

  • 氢谱
    1HNMR
  • 质谱
    MS
  • 碳谱
    13CNMR
  • 红外
    IR
  • 拉曼
    Raman
查看更多图谱数据,请前往“摩熵化学”平台
mass
查看更多图谱数据,请前往“摩熵化学”平台
ir
查看更多图谱数据,请前往“摩熵化学”平台
  • 峰位数据
  • 峰位匹配
  • 表征信息
Shift(ppm)
Intensity
查看更多图谱数据,请前往“摩熵化学”平台
Assign
Shift(ppm)
查看更多图谱数据,请前往“摩熵化学”平台
测试频率
样品用量
溶剂
溶剂用量
查看更多图谱数据,请前往“摩熵化学”平台